The Indian firm will integrate the licensed genes into its R&D pipeline and evaluate them in rice field trials.
The agreement provides Rasi Seeds the right to commercialise hybrid rice incorporating these genes in India and in additional countries in Southeast Asia.
Evogene will be entitled to receive milestone payments and royalties based on the sales of resulting products.
Financial terms of the agreement were not disclosed. Under the collaboration, Rasi Seeds will be granted a license to candidate genes, identified and prioritised through Evogene's Athlete computational genomic technology and validated in model plants.
